Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Seems to me I've heard this song before". Always loved that tune!
NO! 1/3 of 1% !
What kind of a game is this?
There are 200,000 shares available at .0012, with a bid for 199,990 at .0011!
There is a standoff over $20! This is OK Corral stuff!
Way to go guys with the last few posts!
There is a good reason why a company who has filed a Chapter 7 goes over 9 months with no action on the filing.
Don't listen to dismal predictions from those who are clueless!
Luther
What intrigues us here is the potential of what is not obvious, but I expect your message will fall on deaf ears!
My reading on Chapter 7 Bankruptcy indicates that there is a provision for exiting Chapter 7 by changing it to either Chapter 11 or 13. That could be the route by which Rock Creek re-emerges.
Interesting to note, at least interesting to me, that after doing little all day, at 3:38 the stock traded 100,000 shares at .0014. Following that trade the bid was .0009 for 1,200,000 shares, and the ask was .0015 for 10,000 shares.
Attached is a summary report of what Dr Fiona Crawford has been up to in the TBI area. Anatabine results begin on page 20 of its 36 pages.
http://www.nationalacademies.org/hmd/~/media/Files/Activity%20Files/Research/NeuroForum/2017-MAR-20/1-2%20Crawford.pdf
powerwalker
Dr Mullan, as "Exploitation and Scientific Director" of Nilvad has made it clear that the phase 3 study results of Nilvadipine will be submitted to a prestigious scientific publication for peer review and publication. I'm assuming that this was decided by the Nilvad Study team to give the results more credibility.
It's hard to believe that the scientific community and media seem to be totally unaware that the world's first breakthrough in Alzheimer's treatment is soon to be announced.
No they haven't, but could come any day now!
What's wrong with my solution, where the Nilvad Phaze 3 results indicate that Nilvadipine demonstrated some degree of success in interrupting, for THE FIRST TIME IN HISTORY, the progression of Alzheimer's.
That would result in a huge demand for Nilvadipine to treat Alzheimer's, which Archer/Roskamp could license w/royalty. Roskamp could then spinoff Archer, Rock Creek re-emerges as a Delaware corporation, and Archer and Rock Creek merge as equals.
No bidding! No outsiders! Everybody is happy!
I admit you could be right, but we shall see soon enough!
Keep the faith, bonoinvest! The scenario 1manband is seeing doesn't explain why a hopeless bankruptcy remains unsettled 9 months after the Chapter 7 filing.
If someone were dumping 500,000 shares on the market why would the first two trades go off at the lowest price of the day?
Looks to me like that someone stepped in and purchased 500,000 shares, paying the lowest price for shares at the cheapest price available on the first two trades.
Comments?
9 months since Chapter 7 !
6 months since NILVAD wrapped up !
WAITING ! WAITING ! WAITING !
Dr Michael Mullan was back on Facebook today with a repeat of the 5 minute video in which he talks about how researchers have been chasing the pointless "amyloid hypothosis for 25 years. I see this as saying "look here guys, I've got something to tell you about what we have discovered about interrupting the progression of Alzheimer's".
Should be reporting NILVAD RESULTS soon.
The RCPIQ summary for the day makes it appear that the stock tumbled over 57% on heavy volume of 445K shares. In reality it looks like the bulk of those shares traded between .0014 and .0011.
Late in the day a whopping 800 shares traded at .0006.
Took a very good look at Anavex and must admit that I was very, very impressed with just about everything about them including their location.
As to how it compares to Roskamp/Archer/Rock Creek, my only observation is that R/A/RC seem to be significantly ahead, as they expect to release the NILVAD results "by the summer".
powerwalker
Thanks for the heads up on Anavex, it looks very interesting. Looking forward to digging into their IP.
I vote to remove his photo, IF IF IF he doesn't get the Noble Prize In Medicine for his work in Alzheimer's Disease!
Here is the link to the 66 minute talk.
https://video.search.yahoo.com/yhs/search?fr=yhs-mozilla-001&hsimp=yhs-001&hspart=mozilla&p=roskamp+institute+youtube#id=1&vid=05ad335c9082c707bf87124c1213bf1e&action=click
CORRECTION:
In the 2 1/2 minute tribute to Roskamp which begins at about 43:30, Dr Mullan says the Institute can spin off for-profit companies, and can partner with for-profit companies.
idcc
Everyone's crystal ball is so foggy that seeing into the future for RCPIQ is impossible. Roskamp/Archer must necessarily keep its plans from its probable competitors.
I refer you to message #28140 for what I would like to see happen.
For anyone desperate for any tidbit of hope, I suggest you listen again to the recent 66 minute talk Dr Mullan gave on Alzheimer's. Beginning at about 43:30 he digressed from his talk to pay tribute to the Roskamps and Roskamp Institute, saying that the Institutes flexibility enables it to spin off for-profit companies, and to acquire for-profit companies. To me that was a subtle hint to those of us who are asking the question you are asking.
Look who is delivering the lead off presentation @ 8:05 AM Wed. @the Annual TBI Conference in Washington DC.
tbiconference.com/home/2017agenda
Thanks for catching that, Luther! I wrongly assumed these were already published studies, so didn't look at them.
Actually, there were nearly a half dozen studies, newly published this Spring, mostly relating to Alzheimer's, and one to GWI. Pretty technical, but sound very significant.
I believe this is a new site as it was previously marked "COMING SOON".
http://www.mullanalzheimer.com/
What marriage, Carole? The FDA has made it pretty clear that anatabine does not sell in the USA unless it's an approved drug!!!
"There's a new mouse study out on TBI treated with anatabloc"
Should we just take your word about the "new mouse study",or would you like to tell us where you saw this?
By the way,welcome to the board.
At 3 PM asking price is .0014 for 16,100 shares. Bid is .0013 for 1,016,100.
GO FIGURE ??????????????????????????????
At one point today 90,000 shares were at an asking price of .0014 when 84,000 shares had already been traded. I was in the process of placing a bid for 90,000 @ .0014 when the quote showed the shares no longer available. The shares traded showed 174,000, and the last trade price was .0014.
These trades are lottery tickets which could leave the buyer empty handed at one extreme, to wealthy at the other extreme. I like the odds!
Here is a paper of interest just published yesterday:
http://www.alzforum.org/news/research-news/brain-inflammation-drastically-changes-behavior-and-lifespan-animals
There is much to read here, but this paragraph near the end is the most interesting to most of us here.
“The paper shows for the first time that both increase and decrease of NF-kB activity , and therefore of immune activity, can determine lifespan,” said Ligoxygakis. “It’s all centered on one molecule.” NF-kB could become a therapeutic target for neurodegenerative diseases, or even prolong health span,” he said, “but the challenge will be to modulate this signaling locally in the brain.”
Seriously? Patrick Cox told us that many years ago!
Here is the link to everything you could ever know about Gulf War Illness:
http://us4.campaign-archive2.com/?u=a028e126972379903e0486443&id=931eb3baea&e=c3680e7bfc
The attached link to the EXPLOITATION phase of the NILVAD STUDY details the effort facing Dr. Mullan and his team once the study results are released. As I have seen elsewhere, the plan is to submit the study results to a proper publication (I hope the New England Journal of Medicine), for peer review and publication. The better the publication, the more impact the results will have.
Positive study results, which Dr. Mullan seems to be signaling would put Archer ahead of the pack with enough of a lead that it will be very difficult for others to catch up, unless someone comes up with a presently unexpected breakthrough. Those who want to board the nilvadipine gravy train will have to get in line and make their bid!
https://www.nilvad.eu/the-project/wp08-exploitation-and-scientific-direction/
Luther
Looks to me like the NILVAD results will be significantly better than the drugs now being used to treat early Alzheimer’s. That alone should guarantee a very significant demand for nilvadipine when Archer gets approval to sell it as a treatment for Alzheimer’s.
My hope is that Roskamp will resist the temptation to keep the whole hog, but rather will license it out to one or more large Pharmas in exchange for license fees and generous royalties, leaving Archer free to focus on a 2nd generation AD drug.
My outlook about the whole Roskamp, Archer, Rock Creek situation is colored by the fact that when the RC shares outstanding were ballooning and the stock price plummeting, I loaded up to where my average cost basis is now under 9 cents, so I hunger for a big win here. Should nilvadipine turn out to be a financial success as I expect, then there will be plenty of money to bail out RC and combine with Archer on equal footing, becoming Archer Rock Creek Pharmaceutical, or ARC Pharma for short, with the symbol ARCP.
Anatabine’s success story can begin with a fairly quick, not too expensive Phase 3 study to prove anatabine’s anti-inflammatory mechanism of action, and the rest will be history!
The big question is will we current holders of Rock Creek shares be a part of this amazing story? Here too, given that Jonnie Williams, Robert Roskamp, and Dr. Michael Mullan are fellow shareholders, we are all in this same boat together.
Anyone else want to get in on this?
Found a YouTube video last night of Dr Mullan speaking to a group of seniors about Alzheimer’s. It runs for an hour and six minutes and was filmed 4/7/17. It mostly is a repeat of things he has said before, but I would recommend to start listening to it from 43:30 where he talks about Roskamp, the Nilvad Study, and Nilvadipine. Incidentally, one slide indicated that the Nilvad Study was completed in Dec. 2016. He noted that one of the advantages of a small lab like Roskamp Institute.was that they can SPIN OFF “FOR PROFIT” companies, and can PARTNER WITH “FOR PROFIT” companies. WAS THAT A NOT SO SUBTLE HINT OF WHAT THEY ARE PLANNING? This good stuff ends at about 46:00.
MineAllMine
I have long assumed that Drs Mullan and Crawford, and Robert Roskamp would love to have anatabine as part of the Roskamp Institute effort, if only because of all the work they have put into developing the science surrounding it.
Attached is a link to the list of drugs currently in trials to determine their potential impact on Alzheimer’s Disease. This year old list estimates the Nilvad trial completion in Dec. 2017, the Reg filing date in Dec. 2018, and the Launch Date in the 3rd Qtr. of 2019. Since they were off about 10 months on the trial completion date, I assume we can adjust their Launch Date 10 months earlier to the 4th Qtr of 2018.
http://www.usagainstalzheimers.org/sites/default/files/RA2_Pipeline_Report.pdf
As I expect that Archer Pharma will be announcing the trial results any day, week, or month now, and that those results will be favorable, Archer and Roskamp should receive a lot of media attention as the first one to impact AD in a significant way. Dr. Mullan then has the task of getting Nilvadipine approved for treating AD as soon as possible. One can only fantasize what the market demand will be, but it should be awesome!
That in turn sets up Rock Creek reapplying as a Delaware corporation, and merging as equals with Archer. Archer brings cash flow and a functioning pharma to the merger, and Rock Creek brings NOLs and a mighty patent position.
Seems like one could spin a mighty future for this fantasy tale!
Luther
As I have said before, if anyone knows anything they sure aren't sharing it. However, I refer you to my message #28091 as to what I HOPE is going on!
NILVAD reports that of the over 500 patients which were recruited to participate in the Study, 448 had completed it when the study ended.
https://www.nilvad.eu/